Combination of celecoxib and calyculin-A inhibits epithelial-mesenchymal transition in human oral cancer cells

References

• Byers LA, Diao LX, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan YH, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. 2013. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 19:279–290.
   PubMed Web of Science ®Google Scholar
• Chen WB, Wang ZX, Jiang CP, Ding YT. 2013. PP2A-mediated anticancer therapy. Gastroent Res Pract. 2013:675429.
   PubMedGoogle Scholar
• Chiang SL, Velmurugan BK, Chung CM, Lin SH, Wang ZH, Hua CH, Tsai MH, Kuo TM, Yeh KT, Chang PY, Yang YH, Ko YC. 2017a. Preventive effect of celecoxib use against cancer progression and occurrence of oral squamous cell carcinoma. Sci Rep. 7:6235
   Web of Science ®Google Scholar
• Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, del Puerto-Nevado L, Rojo F, Garcia-Foncillas J. 2014. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta. 1842:1823–1829.
   PubMed Web of Science ®Google Scholar
• Cui W, Yu CH, Hu KQ. 2005. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res. 11:8213–8221.
   PubMed Web of Science ®Google Scholar
• Eichhorn PJ, Creyghton MP, Bernards R. 2009. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 1795:1–15.
   PubMed Web of Science ®Google Scholar
• Fernandez JJ, Candenas ML, Souto ML, Trujillo MM, Norte M. 2002. Okadaic acid, useful tool for studying cellular processes. Curr Med Chem. 9:229–262.
   PubMed Web of Science ®Google Scholar
• Fujita M, Goto K, Yoshida K, Okamura H, Morimoto H, Kito S, Fukuda J, Haneji T. 2004. Okadaic acid stimulates expression of Fas receptor and Fas ligand by activation of nuclear factor kappa-B in human oral squamous carcinoma cells. Oral Oncol. 40:199–206.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Ali S, Philip P, Wozniak A, Sarkar F. 2006. Dual blockade of epidermal growth factor receptor (EGFR) and cyclooxygenase 2 (COX 2) may be dependent upon the EGFR mutational status in non-small cell lung cancer (NSCLC) cell lines. J Clin Oncol. 24:406s–406s.
   Web of Science ®Google Scholar
• Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E. 2001. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia. 3:53–61.
   Google Scholar
• Hattar K, Savai R, Subtil FSB, Wilhelm J, Schmall A, Lang DS, Goldmann T, Eul B, Dahlem G, Fink L, Schermuly RT, Banat GA, Sibelius U, Grimminger F, Vollmer E, Seeger W, Grandel U. 2013. Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunol Immun. 62:309–320.
   PubMed Web of Science ®Google Scholar
• He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, Xue YP, Huang GC, Sun WH. 2012. Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. Febs J. 279:4201–4212.
   PubMed Web of Science ®Google Scholar
• Hsu LS, Wu PR, Yeh KT, Yeh CM, Shen KH, Chen CJ, Soon MS. 2014. Positive nuclear expression of KLF8 might be correlated with shorter survival in gastric adenocarcinoma. Ann Diagn Pathol. 18:74–77.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Martin B, Brautigan D, Karaki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, Uemura D. 1989. Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 159:871–877.
   Google Scholar
• Jeon YW, Suh YJ. 2013. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. Oncol Rep. 29:819–825.
   PubMed Web of Science ®Google Scholar
• Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC. 2007. Enhancement of glioblastoma radio response by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys. 67:888–896.
   PubMed Web of Science ®Google Scholar
• Kreppel M, Eich HT, Kubler A, Zoller JE, Scheer M. 2010. Prognostic value of the sixth edition of the UICC’s TNM classification and stage grouping for oral cancer. J Surg Oncol. 102:443–449.
   PubMed Web of Science ®Google Scholar
• Kurihara Y, Hatori M, Ando Y, Ito D, Toyoshima T, Tanaka M, Shintani S. 2009. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metas. 26:425–432.
   PubMed Web of Science ®Google Scholar
• Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Half E, Burke CA. 2010. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 105:1437–1443.
   PubMed Web of Science ®Google Scholar
• Macfarlane TV, Murchie P, Watson MC. 2015. Aspirin and other nonsteroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer. Cancer Epidemiol. 39:1015–1022.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. 2000. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:1306–1311.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Neviani P. 2013. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 14:e229–e238.
   PubMed Web of Science ®Google Scholar
• Qian M, Qian DH, Jing HY, Li Y, Ma CY, Zhou YM. 2014. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Oncol Rep. 32:1681–1688.
   PubMed Web of Science ®Google Scholar
• Qin J, Yuan JL, Li L, Liu HL, Qin RL, Qin WJ, Chen BQ, Wang H, Wu KC. 2009. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells. Biomed Pharmacother. 63:241–248.
   PubMed Web of Science ®Google Scholar
• Rekhi B, Ahmed S, Basak R, Qureshi SS, Desai SS, Ramadwar M, Desai SB, Kurkure P, Jambhekar NA. 2012. Desmoplastic small round cell tumor-clinicopathological spectrum, including unusual features and immunohistochemical analysis of 45 tumors diagnosed at a tertiary cancer referral centre, with molecular results t(11;22) (p13; q12) (EWS-WT1) in select cases. Pathol Oncol Res. 18:917–927.
   PubMed Web of Science ®Google Scholar
• Seshacharyulu P, Pandey P, Datta K, Batra SK. 2013. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 335:9–18.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Yoshida K, Okamura H, Morimoto H, Nagata T, Haneji T. 2007. Calyculin A induces apoptosis and stimulates phosphorylation of p65NF-kappa B in human osteoblastic osteosarcoma MG63 cells. Int J Oncol. 31:389–396.
   PubMed Web of Science ®Google Scholar
• Uefuji K, Ichikura T, Mochizuki H. 2000. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 6:135–138.
   PubMed Web of Science ®Google Scholar
• Velmurugan BK, Lee CH, Chiang SL, Hua CH, Chen MC, Lin SH, Yeh KT, Ko YC. 2018a. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential. J Cell Physiol. 233:1300–1311.
   PubMed Web of Science ®Google Scholar
• Velmurugan BK, Lee CH, Chiang SL, Hua CH, Chen MC, Lin SH, Yeh KT, Ko YC. 2018b. PP2A deactivation is a common event in oral cancer and reactivation by FTY720 shows promising therapeutic potential. J Cell Physiol. 233:1300–1311.
   PubMed Web of Science ®Google Scholar
• Voulgari A, Pintzas A. 2009. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Bba-Rev Cancer. 1796:75–90.
   PubMed Web of Science ®Google Scholar
• Wang ZL, Fan ZQ, Jiang HD, Qu JM. 2013. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis. 34:638–646.
   PubMed Web of Science ®Google Scholar
• Westermarck J, Hahn WC. 2008. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 14:152–160.
   PubMed Web of Science ®Google Scholar
• Wu QB, Sun GP. 2015. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World J Gastroenterol. 21:6206–6214.
   PubMedGoogle Scholar
• Xin B, Yokoyama Y, Shigeto T, Futagami M, Mizunuma H. 2007. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer-Am Cancer Soc. 110:791–800.
   PubMed Web of Science ®Google Scholar
• Xing C, Kato S, Matsukura N, Matsuda N, Xu H, Takashi E, Yamada N, Naito Z, Tajiri T. 2005. Interleukin-8, cyclo-oxygenase-2, and trefoil factor family 1 gene expression and their association with Helicobacter pylori infection in the remnant stomach. Surg Today. 35:1026–1032.
   PubMed Web of Science ®Google Scholar
• Xu XF, Xie CG, Wang XP, Liu J, Yu YC, Hu HL, Guo CY. 2008. Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med. 215:149–157.
   PubMed Web of Science ®Google Scholar
• Zhang H, Li ZH, Wang KZ. 2014. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. Oncol Rep. 31:1954–1960.
   PubMed Web of Science ®Google Scholar